{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tamoxifen-managing-adverse-effects/background-information/definition/","result":{"pageContext":{"chapter":{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field 9a170511-3f4f-405f-ad69-5bb31c8a6169 --><h2>What is it?</h2><!-- end field 9a170511-3f4f-405f-ad69-5bb31c8a6169 -->","summary":"","htmlStringContent":"<!-- begin item ae668a52-dd06-4f37-873e-32635bfdc395 --><!-- begin field 763e03ab-dcc8-4629-9a87-e867e42bc09b --><ul><li><strong>Tamoxifen is a selective oestrogen receptor modulator (SERM) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Heery, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>]<strong>.</strong><ul><li>SERMs are nonsteroidal, triphenylethylene-based drugs that bind to oestrogen receptors, resulting in oestrogen agonist or oestrogen antagonist-like effects of varying magnitudes in different tissues.</li><li>Oestrogen receptors exist in many tissues, including the breast, brain, lung, liver, bone, and uterus, and different SERMs have different tissue effects.</li><li>In the breast tissue, for example, tamoxifen acts primarily as an oestrogen antagonist. It blocks the transcriptional activity of oestrogen receptors by directly binding to them, producing a nuclear complex that decreases DNA synthesis and inhibits oestrogen effects.</li></ul></li><li><strong>Tamoxifen is licensed for </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>]<strong>:</strong><ul><li>The treatment of oestrogen-receptor-positive breast cancer.</li><li>The treatment of anovulatory infertility. Patients being treated for infertility should be warned that there is a risk of multiple pregnancy (<em><em>rarely</em></em> more than twins).</li><li>The primary prevention of breast cancer in women at moderate or high risk.</li></ul></li></ul><!-- end field 763e03ab-dcc8-4629-9a87-e867e42bc09b --><!-- end item ae668a52-dd06-4f37-873e-32635bfdc395 -->","topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","lastRevised":"Last revised in November 2019","chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","fullItemName":"Management","slug":"management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}